文献速递泌尿系结石

治疗后肾结石残留碎片的自然史:系统综述与荟萃分析

Natural History of Post-Treatment Kidney Stone Fragments: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Urol · 2021-04-27

该系统综述与荟萃分析评估了治疗后无症状残留肾结石碎片的干预率和疾病进展率。纳入18篇文献共2096例患者,结果显示≤4 mm碎片干预率从19%(20个月)升至22%(50个月),>4 mm从22%升至47%;≤4 mm疾病进展率从25%升至47%,>4 mm从26%升至88%。荟萃分析显示>4 mm碎片干预风险显著更高(OR=1.50,95%CI 0.70-2.30,p<0.001),但疾病进展无显著差异。

要点

  • ≤4 mm残留碎片干预率从19%(20个月)升至22%(50个月)。
  • >4 mm残留碎片干预率从22%(20个月)升至47%(50个月)。
  • >4 mm碎片干预风险显著更高(OR=1.50,95%CI 0.70-2.30)。

核心结论

  • 较大的治疗后残留碎片在长期更可能需要进一步干预。
  • 较小碎片虽干预风险较低,但仍存在干预风险。
  • 不同大小碎片之间的疾病进展率无显著差异。

研究设计与样本

  • 系统综述与荟萃分析,检索Ovid、MEDLINE、Embase、Cochrane Library和ClinicalTrials.gov。
  • 纳入标准为治疗后(冲击波碎石、输尿管镜或经皮肾镜取石)存在残留肾碎片的全部研究。
  • 从273篇文章中纳入18篇,共2096例患者,分析使用R语言metafor包,偏倚评估采用Newcastle-Ottawa量表。

主要发现

  • ≤4 mm碎片总体干预率从19%(20个月)升至22%(50个月)。
  • >4 mm碎片总体干预率从22%(20个月)升至47%(50个月)。
  • ≤4 mm碎片总体疾病进展率从25%升至47%,>4 mm从26%升至88%。
  • >4 mm对比≤4 mm的干预率OR=1.50(95%CI 0.70-2.30),p<0.001,I2=67.6%,tau2=0.48,Cochran's Q=11.4(p=0.02),Egger回归z=3.11,p=0.002。
  • >4 mm对比≤4 mm的疾病进展率OR=0.06(95%CI -0.98-1.10),p=0.91,I2=53.0%,tau2=0.57,Cochran's Q=7.11(p=0.07),Egger回归z=-0.75,p=0.45。

关键数值与推荐

  • 残留碎片按大小分为≤4 mm和>4 mm两组进行比较。
  • 主要结局为干预率和疾病进展率。
  • 偏倚分析显示中等风险。

临床怎么用

  • 对残留碎片患者应进行适当咨询,并就进一步管理进行知情决策。
  • 尤其对>4 mm残留碎片患者,应告知长期可能需要进一步干预的风险。
  • 对≤4 mm残留碎片患者也应告知仍存在干预风险。

局限性

  • 各研究对「疾病进展」的定义存在显著差异。
  • 偏倚分析显示中等风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We assessed the literature around post-treatment asymptomatic residual stone fragments and performed a meta-analysis. The main outcomes were intervention rate and disease progression. MATERIALS AND METHODS: We searched Ovid®, MEDLINE®, Embase™, the Cochrane Library and ClinicalTrials.gov using search terms: "asymptomatic", "nephrolithiasis", "ESWL", "PCNL", "URS" and "intervention." Inclusion criteria were all studies with residual renal fragments following treatment (shock wave lithotripsy, ureteroscopy or percutaneous nephrolithotomy). Analysis was performed using 'metafor' in R and bias determined using Newcastle-Ottawa scale. RESULTS: From 273 articles, 18 papers (2,096 patients) had details of intervention rate for residual fragments. Aggregate intervention rates for ≤4 mm fragments rose from 19% (20 months) to 22% (50 months), while >4 mm fragments rose from 22% to 47%. Aggregate disease progression rates for ≤4 mm rose from 25% to 47% and >4 mm rose from 26% to 88%. However, there was substantial difference in definition of "disease progression." Meta-analysis comparing >4 mm against ≤4 mm fragments: intervention rate for >4 mm (vs ≤4 mm): OR=1.50 (95% CI 0.70-2.30), p <0.001, I2=67.6%, tau2=0.48, Cochran's Q=11.4 (p=0.02) and Egger's regression: z=3.11, p=0.002. Disease progression rate for >4 mm: OR=0.06 (95% CI -0.98-1.10), p=0.91, I2=53.0%, tau2=0.57, Cochran's Q=7.11 (p=0.07) and Egger's regression: z=-0.75, p=0.45. Bias analysis demonstrated a moderate risk. CONCLUSIONS: Larger post-treatment residual fragments are significantly more likely to require further intervention especially in the long term. Smaller fragments, although less likely to require further intervention, still carry that risk. Notably, there is no significant difference in disease progression between fragment sizes. Patients with residual fragments should be appropriately counselled and informed decision-making regarding further management should be done.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Brain E, Geraghty RM, Lovegrove CE, et al. Natural History of Post-Treatment Kidney Stone Fragments: A Systematic Review and Meta-Analysis. J Urol. 2021. PMID: 33904756. doi:10.1097/JU.0000000000001836

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。